SCHEMBL20045016

SCHEMBL20045016

CC(C)(C)c1ncnc(NC2CCOCC2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 9/20 0.50
▸ MAPK8 P45983 1/20 0.41
▸ MAPK9 P45984 1/20 0.41
▸ MAPK10 P53779 1/20 0.41
▸ HDAC3 O15379 1/20 0.40
▸ HDAC1 Q13547 1/20 0.40
▸ HDAC2 Q92769 1/20 0.40
▸ HDAC6 Q9UBN7 1/20 0.40
▸ HRH4 Q9H3N8 1/20 0.40
▸ MKNK1 Q9BUB5 1/20 0.38
▸ MKNK2 Q9HBH9 1/20 0.38
▸ RET P07949 1/20 0.38
▸ PIK3C3 Q8NEB9 1/20 0.37
▸ IRAK4 Q9NWZ3 1/20 0.37
▸ PTGS2 P35354 1/20 0.36
▸ JAK2 O60674 2/20 0.36
▸ JAK1 P23458 2/20 0.36
▸ MAPK14 Q16539 1/20 0.35
▸ TYK2 P29597 1/20 0.35
▸ STAT3 P40763 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18466258 0.75 MALT1 (0.57) MAPK1
SCHEMBL19171094 0.75 MAPK1 (0.57) MAPK1MAPK8MAPK9MAPK10HRH4
SCHEMBL23559865 0.73 MAPK1 (0.68) MAPK1MAPK8MAPK9MAPK10HDAC3
SCHEMBL24650700 0.72 MAPK1 (0.57) MAPK1MAPK8MAPK9MAPK10HDAC3
SCHEMBL18466033 0.70 MAPK1 (0.43) MAPK1HRH4IRAK4JAK2JAK1
SCHEMBL5966376 0.69 NPSR1 (0.49) MAPK1MAPK8MAPK9MAPK10HRH4
SCHEMBL15830033 0.69 MAPK1 (0.62) MAPK1MAPK8MAPK9MAPK10HRH4
SCHEMBL16217391 0.69 IRAK4 (0.47) MAPK1IRAK4JAK2JAK1
SCHEMBL2568620 0.68 MAPK1 (1.00) MAPK1HDAC3HDAC1HDAC2HDAC6
SCHEMBL19144932 0.67 MAPK1 (1.00) MAPK1MAPK8MAPK9MAPK10HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180098987-A1 PRMT5 Inhibitors and Uses Thereof Epizyme, Inc. (US) 2018-04-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180098987-A1 PRMT5 Inhibitors and Uses Thereof PRMT5, PRMT1, PRMT6 MAPK1 904/4885MAPK8 1232/4885MAPK9 443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback